301 related articles for article (PubMed ID: 32139402)
1. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models.
Hernandez AL; Young CD; Bian L; Weigel K; Nolan K; Frederick B; Han G; He G; Devon Trahan G; Rudolph MC; Jones KL; Oweida AJ; Karam SD; Raben D; Wang XJ
Clin Cancer Res; 2020 Jun; 26(12):3058-3070. PubMed ID: 32139402
[TBL] [Abstract][Full Text] [Related]
2. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
[TBL] [Abstract][Full Text] [Related]
3. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
[No Abstract] [Full Text] [Related]
4. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
6. SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.
Ozawa H; Ranaweera RS; Izumchenko E; Makarev E; Zhavoronkov A; Fertig EJ; Howard JD; Markovic A; Bedi A; Ravi R; Perez J; Le QT; Kong CS; Jordan RC; Wang H; Kang H; Quon H; Sidransky D; Chung CH
Clin Cancer Res; 2017 Sep; 23(17):5162-5175. PubMed ID: 28522603
[No Abstract] [Full Text] [Related]
7. Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer.
Tanaka M; Sasaki M; Suzuki T; Nishie H; Kataoka H
Biochem Biophys Res Commun; 2021 Feb; 539():1-7. PubMed ID: 33388624
[TBL] [Abstract][Full Text] [Related]
8. MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma.
Berggren KL; Restrepo Cruz S; Hixon MD; Cowan AT; Keysar SB; Craig S; James J; Barry M; Ozbun MA; Jimeno A; McCance DJ; Beswick EJ; Gan GN
Oncogene; 2019 Nov; 38(48):7329-7341. PubMed ID: 31417185
[TBL] [Abstract][Full Text] [Related]
9. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
10. Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.
de Haan R; van Werkhoven E; van den Heuvel MM; Peulen HMU; Sonke GS; Elkhuizen P; van den Brekel MWM; Tesselaar MET; Vens C; Schellens JHM; van Triest B; Verheij M
BMC Cancer; 2019 Sep; 19(1):901. PubMed ID: 31500595
[TBL] [Abstract][Full Text] [Related]
11. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
12. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
[TBL] [Abstract][Full Text] [Related]
13. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
15. Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas.
Hernandez AL; Wang Y; Somerset HL; Keysar SB; Aisner DL; Marshall C; Bowles DW; Karam SD; Raben D; Jimeno A; Varella-Garcia M; Wang XJ
Mol Carcinog; 2019 May; 58(5):666-673. PubMed ID: 30575147
[TBL] [Abstract][Full Text] [Related]
16. Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.
Moutafi M; Koliou GA; Papaxoinis G; Economopoulou P; Kotsantis I; Gkotzamanidou M; Anastasiou M; Pectasides D; Kyrodimos E; Delides A; Giotakis E; Papadimitriou NG; Panayiotides IG; Perisanidis C; Fernandez AI; Xirou V; Poulios C; Gagari E; Yaghoobi V; Gavrielatou N; Shafi S; Aung TN; Kougioumtzopoulou A; Kouloulias V; Palialexis K; Gkolfinopoulos S; Strati A; Lianidou E; Fountzilas G; Rimm DL; Foukas PG; Psyrri A
Cancer Res Commun; 2023 Aug; 3(8):1514-1523. PubMed ID: 37575280
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol selectively induces DNA Damage, independent of Smad4 expression, in its efficacy against human head and neck squamous cell carcinoma.
Tyagi A; Gu M; Takahata T; Frederick B; Agarwal C; Siriwardana S; Agarwal R; Sclafani RA
Clin Cancer Res; 2011 Aug; 17(16):5402-11. PubMed ID: 21705453
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
19. Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition.
Mattoo AR; Joun A; Jessup JM
Mol Cancer Res; 2019 Jan; 17(1):42-53. PubMed ID: 30201826
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
Kwon M; Jang H; Kim EH; Roh JL
Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]